中國分享抗COVID-19藥物治療的新進展

中國分享抗COVID-19藥物治療的新進展

China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the novel coronavirus disease (COVID-19), according to an official Tuesday.

周二，據(jù)官方消息，中國已經(jīng)完成了抗病毒藥物Favipiravir的臨床研究，該藥物對新型冠狀病毒病(COVID-19)表現(xiàn)出良好的臨床療效。

Favipiravir, the influenza drug which was approved for clinical use in Japan in 2014, has shown no obvious adverse reactions in the clinical trial, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference.

中國科技部國家生物技術發(fā)展中心主任張新民在新聞發(fā)布會上表示，2014年被批準在日本臨床使用的流感藥物Favipiravir在臨床試驗中沒有出現(xiàn)明顯的不良反應。

More than 80 patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, south China's Guangdong Province, including 35 patients taking Favipiravir and 45 patients on a control group. Results showed that patients receiving Favipiravir treatment turned negative for the virus in a shorter time compared with patients in the control group.

在中國南方廣東省深圳市第三人民醫(yī)院，80多名患者參加了臨床試驗，其中35名患者服用了Favipiravir，45名患者為對照組。結(jié)果顯示，與對照組相比，接受Favipiravir治療的患者在較短時間內(nèi)轉(zhuǎn)為陰性。

A multi-centered randomized clinical study led by the Zhongnan Hospital of Wuhan University also suggested that the therapeutic effect of Favipiravir is much better than that of the control group.

武漢大學中南醫(yī)院領導的一項多中心隨機臨床研究也表明，F(xiàn)avipiravir的療效明顯優(yōu)于對照組。

Favipiravir has been recommended to medical treatment teams and should be included in the diagnosis and treatment plan for COVID-19 as soon as possible, Zhang said.

張新民表示，F(xiàn)avipiravir已經(jīng)被推薦給醫(yī)療隊，應該盡快被納入COVID-19的診斷和治療計劃。

A Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the drug and ensure stable supply, Zhang added.

張新民補充說，一家中國制藥公司已經(jīng)獲得國家藥品監(jiān)督管理局的批準，可以批量生產(chǎn)該藥，并確保穩(wěn)定的供應。

China is also pushing forward the utilization of some advanced technologies such as stem cell and artificial liver and blood purification in the treatment of severe cases.

中國還在推進利用干細胞、人工肝、血液凈化等先進技術治療重癥患者。

Zhang said stem cell therapy proves effective in reducing severe inflammatory reactions caused by COVID-19, as well as reducing lung injury and pulmonary fibrosis in patients.

張新民說，干細胞治療被證明在減少COVID-19引起的嚴重炎癥反應，以及減少患者的肺損傷和肺纖維化方面是有效的。

China has initiated several clinical research programs on stem cell therapy against COVID-19, including a stem cell drug that has been approved for clinical trial and a mesenchymal stem cell therapy.

中國已經(jīng)啟動了多個針對COVID-19的干細胞治療的臨床研究項目，包括一種已被批準用于臨床試驗的干細胞藥物和一種間充質(zhì)干細胞治療。

Stem cell therapy has been used to treat 64 patients in severe and critical condition. Those patients' breathing difficulties were gradually relieved and they were generally cured in eight to 10 days. The therapy also showed advantages in preventing pulmonary fibrosis and improving the long-term prognosis for patients.

應用干細胞治療危重癥64例?；颊吆粑щy逐漸緩解，一般在8 ~ 10天內(nèi)治愈。本療法在預防肺纖維化和改善患者遠期預后方面也有一定的優(yōu)勢。

The Chinese Society for Cell Biology and the Chinese Medical Association have jointly issued a guideline to standardize the clinical research and application of stem cell therapy against COVID-19.

中國細胞生物學學會、中華醫(yī)學會聯(lián)合發(fā)布《關于規(guī)范COVID-19干細胞治療臨床研究和應用的指導意見》。

Zhang said China is trying to use artificial liver and blood purification technology to treat critically ill patients. Patients receiving this treatment have seen reduced levels of inflammatory factors and improvement in chest imaging. Their time on ventilator support has been decreased by an average of 7.7 days and the required ICU monitoring time has been shortened.

張新民說，中國正在嘗試使用人工肝和血液凈化技術來治療危重病人。接受這種治療的患者炎癥因子水平降低，胸部影像學改善。平均減少呼吸機支持時間7.7天，縮短了ICU監(jiān)護時間。